Preferred Label : Alpha-Gal AGI-134;
NCIt synonyms : Anti-alpha Gal Immunotherapeutic AGI-134; aGal AGI-134;
NCIt related terms : AGI-134;
NCIt definition : A synthetic alpha Gal (aGal) molecule, with potential immunomodulating and antineoplastic
activities. Upon intratumoral injection of aGal AGI-134, aGal coats the cancer cell
membranes and triggers an anti-aGal antibody-mediated immune response leading to an
initial complement-dependent and antibody-dependent cellular cytotoxicity (ADCC).
This cytotoxicity causes release from tumor cells and subsequent uptake of released
tumor-associated antigens (TAAs) by antigen-presenting cells (APCs). This may activate
a systemic immune response against the TAAs and may eradicate cancer cells. aGal is
a cell-surface carbohydrate antigen not expressed by humans while being expressed
by all other mammals and bacteria. Anti-aGal antibodies are continuously and abundantly
produced by humans due to exposure to aGal present on intestinal bacteria in the digestive
system.;
UNII : OE0L4ZX3I8;
CAS number : 1821461-84-0; a href https://gsrs.ncats.nih.gov/ginas/app/beta/browse-substance?search 1821461-84-0
alt lien vers site G-SRS target _blank img src /img/logos/logo_g-srs.png alt Logo
G-SRS /a ;
Molecule name : AGI 134; AGI-134;
NCI Metathesaurus CUI : CL978678;
Origin ID : C165548;
UMLS CUI : C5237258;
Semantic type(s)
- concept_is_in_subset
